Over the past year, we have seen a worrying trend emerge in our clinic: clients with long-standing histories of bulimia nervosa and binge eating disorder are now presenting with anorexia nervosa – not through a natural progression of their illness, but following the use of GLP-1 receptor agonists like Ozempic and Wegovy.
These medications, originally developed for diabetes and now widely prescribed (and in some cases bought online) for weight loss, suppress appetite and can trigger rapid, dramatic weight loss. For individuals with an eating disorder history, this can be catastrophic.
A New Pathway to Anorexia
Traditionally, eating disorder trajectories have been somewhat predictable – bulimia might develop from restrictive dieting, or binge eating disorder might follow years of disordered restraint. What we are now witnessing is different: GLP-1 medications accelerating people from binge/purge cycles into severe restriction.
Clients who once felt trapped in patterns of loss of control & overeating, now find themselves able to restrict and lose weight without the cycle of bingeing which follows. The medication effectively enables a physiological restriction – a dangerous and seductive state for someone desiring weight loss who struggles with unrelenting standards leading to a vulnerability to anorexia nervosa.
Most individuals present for psychological support when they feel overwhelmed with distressing symptoms. In eating disorders it’s usually the binge eating or purging which drives this for the majority of eating disorder presentations. When these symptoms are no longer present and they are losing weight rapidly instead, these clients are unlikely to present to services until they are suffering from symptoms of severe malnutrition.
The Risk of Uncontrolled Access in the UK
The ease with which these drugs can be obtained is deeply concerning. While NHS criteria for prescribing are clear, private providers and online pharmacies often operate with far fewer safeguards. For a motivated individual – perhaps already distressed about weight, body image, or eating – access is frighteningly simple.
This raises important questions:
- How many people with eating disorder histories are being prescribed these drugs without appropriate screening?
- What responsibility do prescribers have to assess psychological as well as physical risk?
- Where is the regulation to prevent misuse or casual prescribing in vulnerable groups?
- Is anyone recording the prevalence of abuse of these medications and medical complications?
Moving Forward
As eating disorder specialists, we are increasingly encountering this overlap between GLP-1 use and disordered eating. Awareness is essential – for clinicians, prescribers, and for those living with or recovering from an eating disorder.
While GLP-1 medications may be appropriate for some individuals, for those with eating disorder vulnerabilities they can represent a significant risk. It is important that people know support is available, and that conversations about both physical and psychological risks become part of routine practice.
At Robur Clinic, we continue to adapt our work to meet the changing landscape of eating disorders, including the emerging impact of weight loss medications. If you are struggling with your relationship with food, whether connected to GLP-1 medication or not, our team is here to help.
